phrykt

United Therapeutics (UTHR) revenue: $3.2B

United Therapeutics reported $3.2B of revenue for the year ended Dec 31, 2025, up 10.6% from $2.9B a year earlier.

From United Therapeutics's filings with the SEC · Read the filing · UTHR stock page

United Therapeutics revenue by year

$1.7B2021$1.9B2022$2.3B2023$2.9B2024$3.2B2025

#927 of 3,622 US companies by revenue · See the full ranking

Year endedRevenueChange
Dec 31, 2025$3.2B+11%
Dec 31, 2024$2.9B+24%
Dec 31, 2023$2.3B+20%
Dec 31, 2022$1.9B+15%
Dec 31, 2021$1.7B–

Revenue of similar companies

Companies in the same industry as United Therapeutics, by SEC industry code, with the closest revenue. Each name opens the same page for that company.

CompanyRevenue, latest yearYear ended
Jazz Pharmaceuticals$4.3BDec 31, 2025
PERRIGO$4.3BDec 31, 2025
Alnylam Pharmaceuticals$3.7BDec 31, 2025
Biomarin Pharmaceutical$3.2BDec 31, 2025
United Therapeutics$3.2BDec 31, 2025
Amneal Pharmaceuticals$3BDec 31, 2025
Royalty Pharma$2.4BDec 31, 2025

Questions and answers

What is United Therapeutics's revenue?

United Therapeutics reported $3.2B of revenue for the year ended Dec 31, 2025, up 10.6% from $2.9B a year earlier.

Numbers as reported in United Therapeutics's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology